08/09/2026 Vor Bio announced the completion of enrollment in its Phase 3 trial of telitacept in gMG Spyre Therapeutics announced Phase 2 Part A induction results for SPY003 in UC Alebund Pharmaceuticals announced FDA clearance of its IND application for AP308 for the treatment of IgA Nephropathy Greywolf Therapeutics dosed the first participant with axSpA in the Ph1/2 trial of GRWD0715. Vor Bio announced the completion of enrollment in its Phase 3 trial of telitacept in gMG.

08/06/2026 Telitacicept received NMPA conditional approval for the treatment of IgA Nephropathy in China Telitacicept received NMPA approval for the treatment of Sjögren’s disease in China Alvotech announced FDA acceptance of a BLA for AVT16, a proposed interchangeable biosimilar to Entyvio® Telitacicept received NMPA conditional approval for the treatment of IgA Nephropathy in China (Ref) Vor Bio and RemeGen Co. announced that China’s National Medicinal Products Administrati